Application No.: 10/643,003 3 Docket No.: 02291/100H204-US1

AMENDMENTS TO THE CLAIMS

- 1. (Original) A composition for treating a patient suffering from vaginitis, a disturbance of the vaginal bacterial flora or bacterial vaginosis, wherein said vaginitis, disturbance of the vaginal bacterial flora or bacterial vaginosis are accompanied with a reduction of the number of Grampositive bacilli, said composition comprising:
 - (a) Sucrose and/or maltose in a concentration of from about 2.5% to about 17% w/v based on the total volume of the composition,
 - (b) An anti-fungal drug in a concentration of from about 0.0001% to about 5% w/v based on the total volume of the composition, and
 - (c) A sufficient amount of a pharmaceutically acceptable acid or alkali, which results in a pH of the composition from about 4.1 to about 7.2.
- 2. (Original) The composition according to claim 1, wherein said composition further comprising one or more saccharides selected from the group consisting of glucose, fructose, galactose, mannose, lactose, lactulose, mycose, cellobiose, melibiose, melitose, malto-oligosaccaride, iso-malto-oligosaccharide and oligo-fructose, dextrin, starch and glycogen.
- (Original) The composition according to claim 1, wherein the content of sucrose and/or maltose in said composition is from about 8% to about 14% w/v.

Application No.: 10/643,003 4 Docket No.: 02291/100H204-US1

4. (Original) The composition according to claim 1, wherein the content of said anti-fungal drug in said composition is from about 0.001% to about 0.5% w/v.

- 5. (Canceled)
- 6. (Original) The composition according to claim 1, wherein the anti-fungal drug is selected from the group consisting of Fluconazole, Terconazole, Tioconazole, Butoconazole, Ketoconazole, Itraconazole, Econazole, Miconazole and Cannitracin.
- 7. (Original) The composition according to Claim 6, wherein each antifungal drug is selected from the group consisting of Fluconazole, Terconazole and Tioconazole.
- 8. (Original) The composition according to claim 1, wherein the composition is in the form of hydro gel or ointment, or in the form of liquid for preparing intravagival tampon.
- 9. (Original) The composition according to claim 8, wherein the composition is in the form of hydro gel or ointment and it further comprises of pharmaceutically acceptable viscous base.
- 10. (Original) The composition according to Claim 9, wherein said pharmaceutically acceptable viscous base is Xanthan gum.
- 11. (Original) A method for treating a patient suffering from vaginitis, a disturbance of the vaginal bacterial flora or bacterial vaginosis, wherein said vaginitis, disturbance of the vaginal bacterial flora or bacterial vaginosis are accompanied with a reduction of the number of Grampositive bacilli, said method comprising vaginally administering to a

Application No.: 10/643,003 5 Docket No.: 02291/100H204-US1

subject in need of such treatment a therapeutically effective amount of a composition comprising:

- (a) Sucrose and/or maltose in a concentration of from about 2.5% to about 17% w/v based on the total volume of the composition,
- (b) An anti-fungal drug in a concentration of from about 0.0001% to about 5% w/v based on the total volume of the composition, and
- (c) A sufficient amount of a pharmaceutically acceptable acid or alkali, which results in a pH of the composition from about 4.1 to about 7.2;

wherein said administration promotes selective growth of grampositive bacilli in the vagina of said subject.

12. (Original) A method for treating a patient suffering from vaginitis, a disturbance of the vaginal bacterial flora or bacterial vaginosis, wherein said vaginitis, disturbance of the vaginal bacterial flora or bacterial vaginosis are accompanied with a reduction of the number of Grampositive bacilli, said method comprising, simultaneously or sequentially, vaginally administering to a subject in need of such treatment a therapeutically effective amount of composition (A) and composition (B), wherein

Composition (A) comprises:

- (d) Sucrose and/or maltose in a concentration of from about 2.5% to about 17% w/v based on the total volume of the composition, and
- (e) A sufficient amount of a pharmaceutically acceptable acid or alkali, which results in a pH of the composition from about 4.1 to about 7.2; and

Application No.: 10/643,003 6 Docket No.: 02291/100H204-US1

Composition (B) comprises:

- (a) An anti-fungal drug in a concentration of from about 0.0001% to about 5% w/v based on the total volume of the composition, and
- (b) A sufficient amount of a pharmaceutically acceptable acid or alkali, which results in a pH of the composition from about 4.1 to about 7.2.
- (Original) The method according to claim 12, wherein said composition(A) and composition (B) are vaginally administering to a subject in need of such treatment simultaneously.